Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

SHILPA MEDICARE LTD. - 530549 - Closure of Trading Window

 With reference to the above subject, we would like to inform you that pursuant to 'Code of Conduct for Regulating, Monitoring and Reporting Trading by Designated Persons and their Immediate Relatives', the Trading Window for dealing in the securities of the Company shall remain closed for all the designated persons and their immediate relatives as covered under the said Code with effect from 01 January 2023 till 48 hours after the declaration of Un-audited Financial Results of the Company for the quarter/nine months ended 31 December 2022.
29-12-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Shilpa Medicare Limited- Launch Of Shilpa'S New Brand Capebel (Capecitabine 1000 MG Dispersible Tablet)

 Shilpa Medicare Ltd, a Raichur (Karnataka) based pharmaceutical company, dedicated in providing world class Oncology and Non-Oncological products to patients across the geographies, announces yet another innovation in treatment of Colorectal and Metastatic Breast Cancer. The company has introduced Capecitabine 1000 MG dispersible tablet for the first time in the world, with novel technology of faster dispersion within 90 seconds. The Company has launched the product in the Indian market on 16th Dec'22 and is further looking to introduce Capebel 1 gm DT in various international markets through our partners and clients.
16-12-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Shilpa Medicare Limited, Unit IV, Jadcherla, Telangana Facility Has Received Health Canada GMP Approval

 This is to inform you that the Company's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval for the inspection conducted from September 12, 2022 to September 16, 2022. The facility is involved in manufacturing, packaging, labelling and testing of finished dosage forms (sterile injections and oral solids) for the treatment of cancer and adjuvant therapy. This GMP approval will allow the company for the commercial distribution of products in Canada and enable new application submissions to Health Canada. This approval reaffirms the company's focused efforts to maintain the GMP status up to the standards of global regulatory authorities. This is for your information and doing the needful
30-11-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Submission Of Related Party Transactions For The Half Year Ended 30 September 2022

 In compliance with Regulation 23 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find herewith enclosed the Related party transactions for the half year ended 30 September 2022.
24-11-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 In furtherance to our intimation dated 12th November 2022 & 14th November 2022 with regard to the Q2 H1 FY23 Conference Call held on Monday, 14th November 2022 at 11.30 AM IST, please find the enclosed revised transcript of the call.
21-11-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.

 The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on November 19, 2022 for Deepak Kumar Innani
21-11-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.

 The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on November 18, 2022 for Deepak Kumar Innani
21-11-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

 The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 19, 2022 for Deepak Kumar Innani
21-11-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

 The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 18, 2022 for Deepak Kumar Innani
21-11-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 In furtherance to our intimation dated 12th November 2022 & 14th November 2022 with regard to the Q2 H1 FY23 Conference Call held on Monday , 14th November 2022 at 11.30 AM IST, please find the enclosed transcript of the call.
17-11-2022
Next Page
Close

Let's Open Free Demat Account